1
|
Ma S, Ma R, Xia T, Afnan M, Song X, Xu F, Hao G, Zhu F, Han J, Zhao Z. Efficacy and safety of Ding-Kun-Dan for female infertility patients with predicted poor ovarian response undergoing in vitro fertilization/intracytoplasmic sperm injection: study protocol for a randomized controlled trial. Trials 2018; 19:124. [PMID: 29458401 PMCID: PMC5819272 DOI: 10.1186/s13063-018-2511-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2017] [Accepted: 01/29/2018] [Indexed: 12/05/2022] Open
Abstract
Background Women undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) who have a predicted poor ovarian response (POR) present a challenge for reproductive medicine specialists. Traditional Chinese medicine (TCM) is commonly used in China for such patients, in the belief that it will improve the ovarian response and ultimately increase pregnancy rates. However, there is a lack of high-quality evidence about the effect of TCM on improving ovarian response in such patients. The purpose of this study is to evaluate ongoing viable pregnancy rate at 12 weeks’ gestation and related indicators of ovarian response in fertile women who have a predicted poor ovarian response having immediate versus delayed IVF/ICSI after 3 months of Ding-Kun-Dan (DKD) pre-treatment. Methods/design This study is a multicenter, randomized controlled, parallel-group, phase III, superiority clinical trial. Two hundred and seventy-eight eligible female infertility patients with POR will be included in the study and randomly allocated into an immediate treatment group and a DKD group in a 1:1 ratio. Both groups will receive IVF or ICSI as a standard treatment while in the DKD group, a commercially available Chinese medicine, DKD, will be administrated for 3 months before the IVF/ICSI cycle starts. The primary outcome of the study is the ongoing pregnancy rate at 12 weeks’ gestation. The secondary outcomes include total gonadotropin dosage, duration of stimulation, estradiol (E2) and progesterone (P) levels on human chorionic gonadotropin (hCG) trigger day, cycle cancellation rate, number of oocytes retrieved, high-quality embryo rate, biochemical pregnancy rate, the change of serum anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), and E2 levels and all side effects, safety outcomes, and any adverse events. The protocol was approved by the Ethics Committee of the First Teaching Hospital of Tianjin university of TCM (approval no. TYLL2017[K] 004). Discussion IVF/ICSI is increasingly used to treat couples desiring a baby. Many of these women will have poor ovarian function. In China, DKD is commonly used for these patients prior to undergoing IVF/ICSI. There is no effective treatment for poor ovarian response in Western medicine currently. It is important, therefore, to undertake this randomized control trial to determine whether DKD is effective or not. Trial registration Chinese Clinical Trial Registry, ID: ChiCTR-IOR-17011697. Registered on 19 June 2017. Electronic supplementary material The online version of this article (10.1186/s13063-018-2511-0) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Saihua Ma
- Reproductive Center, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 Chang Ling Street, Xi Qing district, Tianjin, 300112, China
| | - Ruihong Ma
- Reproductive Center, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 Chang Ling Street, Xi Qing district, Tianjin, 300112, China
| | - Tian Xia
- Reproductive Center, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 Chang Ling Street, Xi Qing district, Tianjin, 300112, China.
| | - Masoud Afnan
- Center of Reproductive Medicine, Tianjin United Family Hospital and Clinics, No. 22 Tanjiang Street, Hexi district, Tianjin, 300221, China
| | - Xueru Song
- Center of Reproductive Medicine, General Hospital of Tianjin Medical University, No. 154 Anshan Street, Nankai district, Tianjin, 300052, China
| | - Fengqin Xu
- Center of Reproductive Medicine, Tianjin First Center Hospital, No. 24 Fukang Road, Nankai district, Tianjin, 300190, China
| | - Guimin Hao
- Center of Reproductive Medicine, The Second Hospital of Hebei Medical University, No. 215 Heping West Road, Xinhua district, Shijiazhuang, 050000, China
| | - Fangfang Zhu
- The Graduate School, Tianjin University of Traditional Chinese Medicine, No. 312 Anshan West Road, Nankai district, Tianjin, 300073, China
| | - Jingpei Han
- The Graduate School, Tianjin University of Traditional Chinese Medicine, No. 312 Anshan West Road, Nankai district, Tianjin, 300073, China
| | - Zhimei Zhao
- Reproductive Center, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 Chang Ling Street, Xi Qing district, Tianjin, 300112, China
| |
Collapse
|